SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001683168-21-001671
Filing Date
2021-04-30
Accepted
2021-04-30 17:20:41
Documents
6
Period of Report
2020-12-31

Document Format Files

Seq Description Document Type Size
1 AMENDMENT #2 TO THE ANNUAL REPORT cns_10ka2-123120.htm 10-K/A 176598
2 DESCRIPTION OF THE COMPANY'S SECURITIES cns_ex0403.htm EX-4.3 29819
3 CERTIFICATION BY OFFICER cns_ex3101.htm EX-31.1 3500
4 CERTIFICATION BY OFFICER cns_ex3102.htm EX-31.2 3300
5 CERTIFICATION OF OFFICER cns_ex3201.htm EX-32.1 3619
6 CERTIFICATION OF OFFICER cns_ex3202.htm EX-32.2 3395
  Complete submission text file 0001683168-21-001671.txt   221262
Mailing Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027
Business Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027 1-800-946-9185 X701
CNS Pharmaceuticals, Inc. (Filer) CIK: 0001729427 (see all company filings)

IRS No.: 822318545 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-39126 | Film No.: 21879905
SIC: 2834 Pharmaceutical Preparations